Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19

被引：1

作者：

Ramnath, Venktesh R. ^{[1
]}

Zar, Heather J. ^{[2
,3
,4
]}

Malhotra, Atul ^{[1
]}

机构：

[1] UC San Diego Hlth, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92037 USA

[2] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa

[3] Univ Cape Town, SA MRC Unit Child & Adolescent Hlth, Cape Town, South Africa

[4] Red Cross War Mem Childrens Hosp, Cape Town, South Africa

来源：

JOURNAL OF THORACIC DISEASE | 2020年 / 12卷 / 06期

关键词：

CONVALESCENT PLASMA; MEDICINE; CARE;

D O I：

10.21037/jtd-20-2011

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：3031 / 3034

页数：4

共 44 条

[31] The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic
Shyr, Derek
Shyr, Yu
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (02) : 111 - 117
[32] Azithromycin/hydroxychloroquineAcute kidney injury, acute haemolytic anaemia and off-label use for COVID-19 pnuemonia: case report
[J]. Reactions Weekly, 2021, 1837 (1) : 99 - 99
[33] TocilizumabViral myocarditis, increased viral replication and worsening of COVID-19 following off-label use: 2 case reports
[J]. Reactions Weekly, 2020, 1813 (1) : 220 - 220
[34] COVID-19-vaccine/nirmatrelvir+ritonavirLack of efficacy and drug eruption during off-label use: case report
[J]. Reactions Weekly, 2023, 1941 (1) : 154 - 154
[35] Off-label drug use during the COVID-19 pandemic in Africa: topic modelling and sentiment analysis of ivermectin in South Africa and Nigeria as a case study
Nia, Z. Movahedi
Bragazzi, N. L.
Ahamadi, A.
Asgary, A.
Mellado, B.
Orbinski, J.
Seyyed-Kalantari, L.
Woldegerima, W. A.
Wu, J.
Kong, J. D.
[J]. JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2023, 20 (206)
[36] Evaluation of four in silico biomarkers for drug-induced proarrhythmic risk: COVID-19 off-label therapies case study
Passini, Elisa
Zhou, Xin
Trovato, Cristian
Delaunois, Annie
Valentin, Jean-Pierre
Bueno-Orovio, Alfonso
Rodriguez, Blanca
[J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
[37] Three Years Since the FDA Advisory Panel on Drug-Eluting Stents: What Have We Learned about Off-Label Use and Stent Thrombosis?
Naidu, Srihari S.
[J]. JOURNAL OF INVASIVE CARDIOLOGY, 2010, 22 (01): : 20 - 21
[38] Multiple drugsReduced response to vaccine leading to fatal COVID-19 pneumonitis, and lack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1911 (1) : 317 - 317
[39] COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials
Diab, Antonios M.
Carleton, Bruce C.
Goralski, Kerry B.
[J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 99 (06) : 577 - 588
[40] Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximabLack of efficacy, off-label use and COVID-19: 2 case reports
[J]. Reactions Weekly, 2023, 1938 (1) : 438 - 438

← 1 2 3 4 5 →